SYGNATURE TOP LEVEL OVERVIEW

Introduction
-Sygnature Discovery is a fully integrated pre-clinical drug discovery contract research organisation
- Facilities are based in the UK and Canada, and span 8 sites
- Balanced client portfolio; pharmaceutical industry, biotechnology companies, research organisations and venture capital

Quality Metrics
- We have an enviable track record of discovering 44 molecules which have progressed into pre-clinical and clinical testing since 2011; 19 pre-clinical, 12 Phase I, 9 Phase II and 4 Phase III
- 86% of our business is based on repeat customers
-Employees are named as inventors on >170 patent families

Staff
-Sygnature is stable and scalable with>1000 employees
→900 scientists, 80% of which have a PhD
-We are ISO27001 accredited (cyber security)

Excellence in Drug Discovery
-Delivering standalone and integrated services
-Target validation, hit identification, hit to lead, lead optimisation, late lead optimisation, candidate nomination, dose prediction into man
-Disciplines: Computer aided drug design, synthetic and medicinal chemistry, in vitro biology, DMPK, in vivo pharmacology, protein sciences, solid form and formulation
-Therapeutic areas: oncology, neuroscience, immunology, metabolism, infectious diseases